switching between glp-1 agonists ada Summary of the effects on HbA1c during transition after Switching between GLP‐1 receptor agonists
Description
The drugs help with diabetes and weight loss, but they may also treat other conditions
Despite that, the drug was well tolerated, even in patients with end-stage renal disease (ESRD), including those on dialysis
Such results are about double what older weight-loss drugs achieve, according to a 2021 article published in the New England Journal of Medicine
Fudim M, et al
The results of the trial were published in The Lancet on May 2, 2026
GLP-1 receptor agonists are mainly administered through the parenteral route due to poor oral bioavailability and degradation in the GI tract
